Abstract

The proposed studies will include the following two interrelated Specific Aims: 1. Quantification of active and inactive drug forms in patients treated with 9NC. 2. Sensitivity and development of resistance of 9NC in cell lines derived from patients.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21CA071485-02
Application #
2545409
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Project Start
1996-09-30
Project End
1998-09-29
Budget Start
1997-09-30
Budget End
1998-09-29
Support Year
2
Fiscal Year
1997
Total Cost
Indirect Cost

  Institution

Name
Stehlin Foundation for Cancer Research
Department
Type
DUNS #
City
Houston
State
TX
Country
United States
Zip Code
77025